Clinical Trials Browser

Completed × Interventional × lenvatinib × Clear all

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Phase 4 Completed

Thyroid Neoplasms

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03713593 2026-02-05

LEAP-002

Phase 3 Completed

794 enrolled 30 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

Phase 3 Completed

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Endometrial Neoplasms

NCT06138496 2026-01-05

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Completed

Carcinoma, Renal Cell

NCT05532319 2025-12-30

FRONT-1

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03526679 2025-12-05

LEADER

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

Phase 2 Completed

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04700072 2025-10-28

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase 1/2 Completed

89 enrolled 24 charts

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

Neoplasms

NCT04447755 2025-10-03

E7080-G000-231

Phase 2 Completed

127 enrolled 29 charts

Recurrence

NCT04716933 2025-09-09

LEAP-006

Phase 3 Completed

201 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Phase 2 Completed

57 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT04305041 2025-08-29

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05101629 2025-07-23

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03516981 2025-07-01

MK-3475-495

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03517449 2025-06-15

MK-3475-775

Phase 3 Completed

827 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Phase 1 Completed

Carcinoma, Renal Cell

NCT04199104 2025-04-23

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT04676412 2025-04-04

LEAP-007

Phase 3 Completed

107 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Completed

64 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05010668 2025-02-21

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

NCT03477175 2025-01-07

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Phase 2 Completed

40 enrolled 13 charts

Other solid neoplasm

Solid Tumors

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT05485896 2024-09-19

Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

Phase 2 Completed

Carcinoma, Renal Cell

NCT04154189 2024-07-22

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Phase 2 Completed

81 enrolled 22 charts

Recurrence, Osteosarcoma

NCT04193553 2024-06-18

LENVAGIST

Phase 2 Completed

Neoplasm Metastasis

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

Phase 2 Completed

29 enrolled 13 charts

Neoplasms

NCT04444167 2024-04-25

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT04618367 2024-03-06

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Phase NA Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Phase NA Completed

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Phase 2 Completed

3 enrolled 9 charts

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT03006926 2023-12-13

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Phase 1 Completed

104 enrolled 41 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04297254 2023-11-15

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Phase 4 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT04642547 2023-08-01

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Phase NA Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1/2 Completed

117 enrolled 32 charts

Neoplasms, Osteosarcoma